Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice

An investigational breast cancer drug Bayer recently licensed from Systems Oncology has shown strong antitumor responses in mice, offering early clues as to why the German pharma shelled out $25 million for the preclinical asset last September.